Tabula Rasa HealthCare Inc (NASDAQ:TRHC) CEO Calvin H. Knowlton sold 8,270 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $53.68, for a total value of $443,933.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
NASDAQ TRHC traded up $0.87 on Friday, reaching $45.07. The company had a trading volume of 87,769 shares, compared to its average volume of 333,792. The firm has a market cap of $975.18 million, a PE ratio of 132.56 and a beta of 1.51. The company has a current ratio of 1.80, a quick ratio of 1.73 and a debt-to-equity ratio of 1.31. Tabula Rasa HealthCare Inc has a 1-year low of $42.29 and a 1-year high of $91.16.
Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%. The firm had revenue of $60.96 million for the quarter, compared to analysts’ expectations of $59.24 million. Equities research analysts forecast that Tabula Rasa HealthCare Inc will post -0.55 EPS for the current year.
Several equities research analysts have recently issued reports on TRHC shares. Zacks Investment Research raised Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research report on Thursday. Piper Jaffray Companies raised their price target on Tabula Rasa HealthCare from $73.00 to $78.00 and gave the company an “overweight” rating in a research report on Thursday, May 9th. BidaskClub downgraded Tabula Rasa HealthCare from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 23rd. Guggenheim began coverage on shares of Tabula Rasa HealthCare in a research note on Wednesday, April 17th. They set a “neutral” rating and a $58.00 price target for the company. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $99.00 target price on shares of Tabula Rasa HealthCare in a research note on Thursday, February 28th. Five equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $82.12.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Rockland Register and is the sole property of of Rockland Register. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://rocklandregister.com/2019/05/31/tabula-rasa-healthcare-inc-trhc-ceo-sells-443933-60-in-stock.html.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Featured Story: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.